Abstract:RNA splicing, a crucial transesterification-based process by which noncoding regions are removed from premature RNA to create mature mRNA, regulates various cellular functions, such as proliferation, survival, and differentiation. Clinical and functional studies over the past 10 y have confirmed that mutations in RNA splicing factors are among the most recurrent genetic abnormalities in hematologic neoplasms, including myeloid malignancies, chronic lymphocytic leukemia, mantle cell lymphoma, and clonal hematopoiesis. These findings indicate an important role for splicing factor mutations in the development of clonal hematopoietic disorders. Mutations in core or accessory components of the RNA spliceosome complex alter splicing sites in a manner of change of function. These changes can result in the dysregulation of cancer-associated gene expression and the generation of novel mRNA transcripts, some of which are not only critical to disease development but may be also serving as potential therapeutic targets. Furthermore, multiple studies have revealed that hematopoietic cells bearing mutations in splicing factors depend on the expression of the residual wild-type allele for survival, and these cells are more sensitive to reduced expression of wild-type splicing factors or chemical perturbations of the splicing machinery. These findings suggest a promising possibility for developing novel therapeutic opportunities in tumor cells based on mutations in splicing factors. Here, we combine current knowledge of the mechanistic and functional effects of frequently mutated splicing factors in normal hematopoiesis and the effects of their mutations in hematologic malignancies. Moreover, we discuss the development of potential therapeutic opportunities based on these mutations.

The Essential Roles of Small Non-Coding RNAs and RNA Modifications in Normal and Malignant Hematopoiesis

Small noncoding RNAs play superior roles in maintaining hematopoietic stem cell homeostasis

RNA Modifications in Hematologic Malignancies.

Emerging Roles of Epigenetic Regulators in Maintaining Hematopoietic Stem Cell Homeostasis

Long noncoding RNAs and their epigenetic function in hematological diseases

RNA Splicing Factors in Normal Hematopoiesis and Hematologic Malignancies: Novel Therapeutic Targets and Strategies

The non-coding RNA landscape of human hematopoiesis and leukemia

RNA M6a Modification Plays a Key Role in Maintaining Stem Cell Function in Normal and Malignant Hematopoiesis

The functions and clinical significance of circRNAs in hematological malignancies

The research progress of circular RNAs in hematological malignancies

Role of Main RNA Modifications in Cancer: N6-methyladenosine, 5-Methylcytosine, and Pseudouridine

Epigenetic modifications in hematopoietic ecosystem: a key tuner from homeostasis to acute myeloid leukemia

Emerging Roles of Extracellular Vesicles in Normal and Malignant Hematopoiesis

The Progress of Epigenetic Modification in Hematological Malignancies Research

Internal m6A and m7G RNA modifications in hematopoietic system and acute myeloid leukemia

Single‐Cell RNA Sequencing in Hematological Diseases

Epigenetic Regulation in Hematopoiesis and Its Implications in the Targeted Therapy of Hematologic Malignancies

Development and Application of Nanomaterials, Nanotechnology and Nanomedicine for Treating Hematological Malignancies

Recent Progress of CircRNAs in Hematological Malignancies

Post-transcriptional regulation of DEAD-Box RNA helicases in hematopoietic malignancies

N6-methyladenosine RNA Modifications: a Potential Therapeutic Target for AML